A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- 48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events
研究概览
简要总结
This study will determine if administration of sodium nitrite is safe and can improve small vessel blood flow and tissue oxygenation when given as an additional treatment in patients with acute vaso-occlusive crisis (pain crisis) associated with sickle cell disease.
详细描述
Nitric oxide (NO) is a naturally occuring chemical that relaxes blood vessels and helps improve blood flow.
The pain associated with vaso-occlusive crisis (pain crisis) in sickle cell disease is caused in part by lack of oxygen and increased tissue acid because blood flow is blocked by stiff sickle red cells. Administration of sodium nitrite should generate nitric oxide in this area of hypoxia and acidosis and improve blood flow.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 23 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects meeting all of the following criteria will be considered for admission to the study:
- •Male or female subject aged between 8 and 23 years of age; only patients up to the age of 23 will be studied at Childrens Hospital Los Angeles
- •Electrophoretic diagnosis of sickle cell disease;
- •Sudden onset of acute pain involving >=1 sites typical of vaso-occlusive crisis (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest, abdomen, or back that can not be explained by other complications of sickle cell disease or by a cause other than sickle cell disease.);
- •Severe pain requiring parenteral analgesics and hospitalization.
- •Informed consent obtained from a legal representative or from subjects 18 years of age or older before enrollment;
- •Being willing and able to be followed for at least 30 days for evaluation.
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •Clinically significant bleeding;
- •Current drug abuse or participation in methadone program;
- •Episode of pain requiring hospitalization within 2 weeks prior to current admission;
- •Other complications of sickle cell disease including cerebrovascular accident, pulmonary hypertension, or seizure;
- •Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding;
- •Blood pressure less than 25th percentile for the subject's age and sex on admission or at the time of screening;
- •Methemoglobinemia >3%;
- •Anemia with hemoglobin level less than 6 g/dL;
- •Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;
- •History of allergy to nitrites or allergy to other substances characterized by dyspnea and cyanosis;
- •Treatment with allopurinol, a medication that could interfere with nitrite metabolism, within the past 30 days before screening;
- •Treatment with any investigational drug within the past 30 days;
- •Significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months;
- •Any subject judged by the clinical investigator or study manager to be inappropriate for the study.
研究组 & 干预措施
Sodium nitrite injection, USP
Administration if sodium nitrite injection, USP
干预措施: sodium nitrite injection, usp (Drug)
结局指标
主要结局
48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events
时间窗: 48 hours from start of infusion
The primary end points will be to determine if a) a 48-hour sodium nitrite infusion is tolerated without a decrease in mean arterial blood pressure by 15mmHg for greater than 2 hours or development of methemoglobin greater than 5% and b) a 48-hour sodium nitrite infusion is safe as determined by monitoring for adverse events
次要结局
- Secondary End Point(48 hours)
研究者
Thomas Coates
Hematology Division Head
Children's Hospital Los Angeles